Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235376 | 0.88 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL1059539 | 0.87 | HTR2A (0.60) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL23922815 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL21097121 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL21098059 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL2233306 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL11423467 | 0.84 | GAA (0.50) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL1242235 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL30871778 | 0.83 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL15459741 | 0.83 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | claimed |
| WO-2010063002-A2 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-03 | — | — | WO | claimed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20240300894-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-09-12 | — | — | US | disclosed |
| CN-118561872-A | Pyrimido-pyridine biological inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240228434-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-07-11 | — | — | US | disclosed |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024125642-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-117940436-A | 7- (Naphthalene-1-yl) pyrido [4,3-d ] pyrimidine derivative and preparation and application thereof | 上海和誉生物医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024050516-A2 | VARENICLINE RELATED COMPOUNDS AND METHODS FOR TREATING DISEASES AND CONDITIONS INCLUDING TOBACCO USE DISORDER | SPACERX LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-5750735-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5744465-A | Method of inhibiting a β-lactamase enzyme by administering novel 2-thiosubstituted carbapenems | AMERICAN CYANAMID COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1997015556-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1997-05-01 | — | — | WO | disclosed |
| US-5623081-A | USING BENZYLOXYACETALDEHYDE DIMETHYL ETHER, HALOGENATED 1-PHENYLMETHOXY-4-PENTEN-2-OL; CYCLIZATION | LIN YANG-I (US) | 1997-04-22 | — | — | US | disclosed |
| US-5602118-A | A 2-((2-SUBSTITUTED ALKYL)FUR-3-YL)-THIO-),3-CARBOXY-2-CARBOPENEM DERIVATIVES; EFFECTIVE AGAINST BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0617036-A2 | Novel 2-thiosubstituted carbapenems | AMERICAN CYANAMID COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |
| EP-0167451-B1 | A NEW PROCESS FOR PREPARING NOVEL N-(ACYLOXY-ALKOXY) CARBONYL DERIVATIVES USEFUL AS BIOREVERSIBLE PRODRUG MOIETIES FOR PRIMARY AND SECONDARY AMINE FUNCTIONS IN DRUGS | MERCK & CO. INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4916230-A | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0167451-A2 | A new process for preparing novel N-(acyloxy-alkoxy) carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO. INC. (US) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300894-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | HTR2A 2752/4885GAA 2961/4885BCL9 4125/4885 |
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | ADH1C, CNR1, GABRG1 | HTR2A 3951/4885GAA 3240/4885BCL9 2017/4885 |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | HTR2A 2752/4885GAA 2961/4885BCL9 4125/4885 |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | HTR2A 4349/4885GAA 1265/4885BCL9 366/4885 |
| US-20240228434-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | HTR2A 2752/4885GAA 2961/4885BCL9 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.